Primary |
Diagnostic Procedure |
50.0% |
Product Used For Unknown Indication |
29.0% |
Abdominal Pain |
3.1% |
Pain Management |
2.6% |
Lung Neoplasm Malignant |
2.1% |
Hypertension |
1.6% |
Chest Pain |
1.2% |
Back Pain |
1.0% |
Abdominal Pain Lower |
0.9% |
Abdominal Pain Upper |
0.9% |
Computerised Tomogram |
0.9% |
Malignant Melanoma |
0.9% |
Non-alcoholic Steatohepatitis |
0.9% |
Pulmonary Embolism |
0.9% |
Fluid Replacement |
0.7% |
Headache |
0.7% |
Osteoporosis |
0.7% |
Routine Health Maintenance |
0.7% |
Breast Cancer |
0.6% |
Cancer Pain |
0.6% |
|
Urticaria |
19.7% |
Vomiting |
13.6% |
Meningitis Fungal |
8.3% |
No Adverse Event |
7.9% |
Rash |
5.3% |
Pruritus |
4.8% |
Pyrexia |
4.8% |
Renal Failure Acute |
3.9% |
Throat Irritation |
3.5% |
Throat Tightness |
3.5% |
Extravasation |
3.1% |
Tremor |
3.1% |
Erythema |
2.6% |
Loss Of Consciousness |
2.6% |
Rash Maculo-papular |
2.6% |
Anaphylactoid Shock |
2.2% |
Oxygen Saturation Decreased |
2.2% |
Shock |
2.2% |
Sneezing |
2.2% |
Anaphylactic Reaction |
1.8% |
|
Secondary |
Diagnostic Procedure |
46.7% |
Product Used For Unknown Indication |
33.1% |
Abdominal Pain |
2.5% |
Pain Management |
2.3% |
Hypertension |
1.6% |
Lung Neoplasm Malignant |
1.6% |
Chest Pain |
1.4% |
Abdominal Pain Upper |
1.1% |
Routine Health Maintenance |
1.1% |
Percutaneous Coronary Intervention |
1.0% |
Dyspnoea |
0.9% |
Malignant Melanoma |
0.9% |
Acute Myocardial Infarction |
0.8% |
Computerised Tomogram |
0.8% |
Headache |
0.8% |
Non-alcoholic Steatohepatitis |
0.8% |
Nuclear Magnetic Resonance Imaging Abdominal |
0.8% |
Back Pain |
0.6% |
Breast Cancer |
0.6% |
Fluid Replacement |
0.6% |
|
Urticaria |
19.5% |
Vomiting |
10.4% |
Meningitis Fungal |
8.6% |
No Adverse Event |
7.2% |
Pruritus |
5.4% |
Rash |
4.5% |
Throat Irritation |
4.5% |
Tremor |
4.5% |
Drug Reaction With Eosinophilia And Systemic Symptoms |
4.1% |
Rash Maculo-papular |
4.1% |
Blood Creatinine Increased |
3.2% |
Pyrexia |
3.2% |
Throat Tightness |
3.2% |
Erythema |
2.7% |
Extravasation |
2.7% |
Loss Of Consciousness |
2.7% |
Renal Failure Acute |
2.7% |
Anaphylactoid Shock |
2.3% |
Oxygen Saturation Decreased |
2.3% |
Renal Tubular Necrosis |
2.3% |
|
Concomitant |
Low Back Pain |
18.9% |
Therapeutic Embolisation |
17.0% |
Acute Lymphocytic Leukaemia |
11.3% |
Prophylaxis |
9.4% |
Pain |
4.7% |
Product Used For Unknown Indication |
4.7% |
Osteoporosis |
3.8% |
Anaesthesia |
2.8% |
Chronic Hepatitis C |
2.8% |
Coronary Artery Bypass |
2.8% |
Head And Neck Cancer |
2.8% |
Insomnia |
2.8% |
Lumbar Radiculopathy |
2.8% |
Back Pain |
1.9% |
Colitis Ulcerative |
1.9% |
Computerised Tomogram |
1.9% |
Constipation Prophylaxis |
1.9% |
Gastritis |
1.9% |
Hepatic Cirrhosis |
1.9% |
Hepatic Neoplasm Malignant |
1.9% |
|
Meningitis |
31.0% |
Hospitalisation |
11.9% |
Vaginal Haemorrhage |
7.1% |
Cholecystitis Acute |
4.8% |
Nuclear Magnetic Resonance Imaging |
4.8% |
Renal Failure Acute |
4.8% |
Unevaluable Event |
4.8% |
Bradycardia |
2.4% |
Cerebrovascular Accident |
2.4% |
Dehydration |
2.4% |
Dyspnoea |
2.4% |
Enterocolitis |
2.4% |
Headache |
2.4% |
International Normalised Ratio Increased |
2.4% |
Malaise |
2.4% |
Neck Pain |
2.4% |
Oedema |
2.4% |
Photophobia |
2.4% |
Pneumonia |
2.4% |
Pyrexia |
2.4% |
|
Interacting |
Drug Use For Unknown Indication |
100.0% |
|
Renal Tubular Necrosis |
100.0% |
|